Figure 2
Figure 2. G-CSF/dexamethasone mobilization changes the phenotype of granulocytes. (A) Light-cycler confirmation of representative genes. Genes (n = 6 identified as differentially expressed by Agilent Whole Humane Genome microarrays (□) were selected from the overall dataset for confirmation by light cycler real-time PCR () after mobilization with G-CSF/dexamethasone. Data represent the mean ± SD of fold changes in gene expression from the 3 donors used in microarray experiments. Microarray data are presented as the mean fold change of the 3 donors. (B) Flow cytometric analysis of different neutrophil surface receptors. Neutrophils isolated from control donors (□) and those treated with G-CSF/dexamethasone (■) were analyzed for the expression of various surface receptors. Cells were stained with directly labeled monoclonal antibodies and measured by flow cytometry. Results represent the data from 3 independent experiments (mean ± SEM). *P < .05 (significant difference).

G-CSF/dexamethasone mobilization changes the phenotype of granulocytes. (A) Light-cycler confirmation of representative genes. Genes (n = 6 identified as differentially expressed by Agilent Whole Humane Genome microarrays (□) were selected from the overall dataset for confirmation by light cycler real-time PCR () after mobilization with G-CSF/dexamethasone. Data represent the mean ± SD of fold changes in gene expression from the 3 donors used in microarray experiments. Microarray data are presented as the mean fold change of the 3 donors. (B) Flow cytometric analysis of different neutrophil surface receptors. Neutrophils isolated from control donors (□) and those treated with G-CSF/dexamethasone (■) were analyzed for the expression of various surface receptors. Cells were stained with directly labeled monoclonal antibodies and measured by flow cytometry. Results represent the data from 3 independent experiments (mean ± SEM). *P < .05 (significant difference).

Close Modal

or Create an Account

Close Modal
Close Modal